NCT07102004View on ClinicalTrials.gov

Study of MHB088C for Patients With Advanced Solid Malignant Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

515

Participants

Timeline

Start Date

June 20, 2023

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2027

Conditions
Advanced/Metastatic Solid Tumors
Interventions
DRUG

MHB088C for Injection

MHB088C for Injection, an antibody drug-conjugated molecule (ADC) MHB088C will be administered intravenously at a frequency of once every 2 weeks (Q2W) or every 3 week (Q3W).

Trial Locations (1)

Unknown

RECRUITING

Beijing Cancer Hospital, Beijing

All Listed Sponsors
lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY